CLINICAL AND ECONOMIC BURDEN OF METASTATIC UVEAL MELANOMA: A RETROSPECTIVE ANALYSIS OF COMMERCIALLY-INSURED, MEDICARE, AND MEDICAID PATIENTS IN THE UNITED STATES
Author(s)
Patrick Ott, MD, PhD1, Aanan Misra, BSc2, Tiffany Kung, PharmD2, Elizabeth Packnett, MPH3, Kristin Kistler, PhD4, Tasneem Lokhandwala, MS, PhD4, Carolyn Ritterson Lew, PhD3, Gary Palmer, MD, MBA2.
1Dana Farber Cancer Institute, Boston, MA, USA, 2IDEAYA Biosciences, South San Francisco, CA, USA, 3MarketScan by Merative, Ann Arbor, MI, USA, 4Cencora, Conshohocken, PA, USA.
1Dana Farber Cancer Institute, Boston, MA, USA, 2IDEAYA Biosciences, South San Francisco, CA, USA, 3MarketScan by Merative, Ann Arbor, MI, USA, 4Cencora, Conshohocken, PA, USA.
OBJECTIVES: Uveal melanoma (UM) is the most common ocular tumor in adults. Up to 50% of patients with primary UM will develop metastatic disease (mUM), resulting in high morbidity and mortality. Current treatments for mUM include locoregional approaches, systemic therapies, or a combination of both. The economic burden of mUM has not been previously reported. This study characterized the clinical and economic burden of mUM in Commercially-insured, Medicare, and Medicaid patients in the United States.
METHODS: This study was conducted using the Merative MarketScan Commercial, Medicare, and Multi-State Medicaid Databases. Adult patients with two non-diagnostic UM claims ≥30 days apart between 1/1/2016 and 6/30/2025, with first evidence of metastasis (index date) between 1/1/2020 and 6/30/2025, and with ≥6 months of continuous enrollment prior to the index date and 30 days following the index date were included. Treatment patterns, adverse events, all-cause and treatment-related healthcare resource use and expenditures were tabulated during the variable follow-up period.
RESULTS: In total 471 mUM patients were included; 47% Commercially-insured, 43% Medicare, and 10% Medicaid patients. Mean age of mUM patients was 63 (SD: 14); 55% were female. Mean healthcare costs were $29,187 per patient per month (PPPM) (SD: $46,089) and included inpatient and outpatient medical costs, and outpatient pharmacy costs. Inpatient costs were $6,502 PPPM (SD: $28,591) overall, including $4,049 PPPM (SD: $23,619) for ICU admissions. Outpatient medical services (i.e., ER, office, labs, radiology, treatments) were $20,555 PPPM (SD $24,272). Outpatient pharmacy costs were $2,131 PPPM (SD $5,448).
CONCLUSIONS: The clinical and economic burden of mUM is substantial. Most expenditures in mUM patients are associated with outpatient medical services; ICU admissions accounted for ≥60% of inpatient expenditures. Given the substantial costs and historically poor outcomes associated with mUM, therapies that deliver meaningful clinical benefits are needed to support effective use of healthcare resources.
METHODS: This study was conducted using the Merative MarketScan Commercial, Medicare, and Multi-State Medicaid Databases. Adult patients with two non-diagnostic UM claims ≥30 days apart between 1/1/2016 and 6/30/2025, with first evidence of metastasis (index date) between 1/1/2020 and 6/30/2025, and with ≥6 months of continuous enrollment prior to the index date and 30 days following the index date were included. Treatment patterns, adverse events, all-cause and treatment-related healthcare resource use and expenditures were tabulated during the variable follow-up period.
RESULTS: In total 471 mUM patients were included; 47% Commercially-insured, 43% Medicare, and 10% Medicaid patients. Mean age of mUM patients was 63 (SD: 14); 55% were female. Mean healthcare costs were $29,187 per patient per month (PPPM) (SD: $46,089) and included inpatient and outpatient medical costs, and outpatient pharmacy costs. Inpatient costs were $6,502 PPPM (SD: $28,591) overall, including $4,049 PPPM (SD: $23,619) for ICU admissions. Outpatient medical services (i.e., ER, office, labs, radiology, treatments) were $20,555 PPPM (SD $24,272). Outpatient pharmacy costs were $2,131 PPPM (SD $5,448).
CONCLUSIONS: The clinical and economic burden of mUM is substantial. Most expenditures in mUM patients are associated with outpatient medical services; ICU admissions accounted for ≥60% of inpatient expenditures. Given the substantial costs and historically poor outcomes associated with mUM, therapies that deliver meaningful clinical benefits are needed to support effective use of healthcare resources.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE368
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Rare & Orphan Diseases